In combination with low-dose GLP-1s, we believe the clinical benefit increases even more, with higher levels of adherence to GLP-1s, and we are confident that by pivoting to this approach, we will capitalize on the success of GLP-1s and set Allurion up for long-term success. The company also announced that it has submitted its protocol for a prospective, multi-centre study on the combination of the Allurion Program with a low-dose of GLP-1 for weight loss while maintaining muscle mass and increasing GLP-1 adherence to Institutional Review Boards (IRBs) in Europe for approval
Price outliers, either extremely low or high, warrant skepticism
Key Point: Important Update: FDA Ruling on Compounded GLP-1s As of March 2025, the FDA has declared the shortages of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) to be resolved
Cells were stained with fluorophore conjugated antibodies (CD3-BUV737 (BD Biosciences
Whether these safety signals translate equivalently to MC4R -deficient patients - who are predominantly children and adolescents with a distinct metabolic phenotype - remains unknown